112 related articles for article (PubMed ID: 19020220)
1. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine.
Bleicher AG; Kanal E
AJR Am J Roentgenol; 2008 Dec; 191(6):W307-11. PubMed ID: 19020220
[TBL] [Abstract][Full Text] [Related]
2. Assessment of rates of acute adverse reactions to gadobenate dimeglumine: review of more than 130,000 administrations in 7.5 years.
Fakhran S; Alhilali L; Kale H; Kanal E
AJR Am J Roentgenol; 2015 Apr; 204(4):703-6. PubMed ID: 25794059
[TBL] [Abstract][Full Text] [Related]
3. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
Abujudeh HH; Kosaraju VK; Kaewlai R
AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
[TBL] [Abstract][Full Text] [Related]
4. Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
Semelka RC; Hernandes Mde A; Stallings CG; Castillo M
Magn Reson Imaging; 2013 Jan; 31(1):96-101. PubMed ID: 22898688
[TBL] [Abstract][Full Text] [Related]
5. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
6. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
[TBL] [Abstract][Full Text] [Related]
7. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
[TBL] [Abstract][Full Text] [Related]
8. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections.
Aran S; Shaqdan KW; Abujudeh HH
Clin Radiol; 2015 May; 70(5):466-75. PubMed ID: 25626627
[TBL] [Abstract][Full Text] [Related]
9. Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers.
Vogl TJ; Pegios W; McMahon C; Balzer J; Waitzinger J; Pirovano G; Lissner J
AJR Am J Roentgenol; 1992 Apr; 158(4):887-92. PubMed ID: 1546612
[TBL] [Abstract][Full Text] [Related]
10. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T.
Essig M; Lodemann KP; Le-Huu M; Brüning R; Kirchin M; Reith W
Invest Radiol; 2006 Mar; 41(3):256-63. PubMed ID: 16481908
[TBL] [Abstract][Full Text] [Related]
11. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
Bryant BJ; Im K; Broome DR
Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
[TBL] [Abstract][Full Text] [Related]
13. Anaphylaxis to gadobenate dimeglumine (Multihance): a case report.
Kalogeromitros DC; Makris MP; Aggelides XS; Spanoudaki N; Gregoriou SG; Avgerinou G; Rigopoulos DG
Int Arch Allergy Immunol; 2007; 144(2):150-4. PubMed ID: 17536224
[TBL] [Abstract][Full Text] [Related]
14. An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging.
Motosugi U; Bannas P; Bookwalter CA; Sano K; Reeder SB
Radiology; 2016 Apr; 279(1):93-102. PubMed ID: 26473642
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients.
Maurer M; Heine O; Wolf M; Durmus T; Wagner M; Hamm B
Eur J Radiol; 2012 May; 81(5):885-90. PubMed ID: 21555197
[TBL] [Abstract][Full Text] [Related]
16. Cardiac electrophysiologic monitoring after injection of gadobenate dimeglumine versus placebo in healthy volunteers and patients with cardiovascular disease.
Pirovano G; Goodman DB; Halemane U; Venetianer C; Kirchin MA; Spinazzi A
Radiology; 2004 Nov; 233(2):555-65. PubMed ID: 15375224
[TBL] [Abstract][Full Text] [Related]
17. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
[TBL] [Abstract][Full Text] [Related]
18. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
Pediconi F; Catalano C; Padula S; Roselli A; Dominelli V; Cagioli S; Kirchin MA; Pirovano G; Passariello R
AJR Am J Roentgenol; 2008 Nov; 191(5):1339-46. PubMed ID: 18941066
[TBL] [Abstract][Full Text] [Related]
19. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
[TBL] [Abstract][Full Text] [Related]
20. Anaphylactic reaction and cardiac arrest due to gadobenate dimeglumine.
Virtos M; Ruiz S; Mokrane FZ; Rousseau H; Georges B; Fourcade O; Conil JM
Anaesth Crit Care Pain Med; 2015 Aug; 34(4):247-8. PubMed ID: 26004876
[No Abstract] [Full Text] [Related]
[Next] [New Search]
